GC
CSTL icon

Globeflex Capital’s Castle Biosciences CSTL Stock Holding History

Globeflex Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,759
Closed -$92.3K – 410
2026
Q1 		$92.3K Hold
3,759
– – 0.01% 362
2025
Q4 		$146K Buy
+3,759
New +$121K 0.02% 339

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Globeflex Capital's CSTL Position: Q2 2026 in Review

Globeflex Capital sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 3,759 shares — an estimated $92.3K sold.

Globeflex Capital first reported a position in CSTL in Q4 2025 and held it in 2 quarters. The position peaked at $146K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Globeflex Capital reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Globeflex Capital sold 3,759 Castle Biosciences shares in Q2 2026, an estimated $92.3K.
  • Globeflex Capital first reported a position in Castle Biosciences in Q4 2025 and held it in 2 quarters.
  • Globeflex Capital's Castle Biosciences position peaked at $146K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.